OX40 Antibodies With Specific CDR Sequences for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current OX40 agonist antibodies for cancer immunotherapy have limitations in clinical trials, necessitating the development of differentiated antibodies with improved functions to enhance tumor immunity and reduce potential risks.
Innovation Solution
Design and development of antibodies and nanobodies with specific heavy chain variable regions comprising particular complementarity-determining regions (CDRs) that bind to OX40 with high affinity, potentially offering enhanced activation of effector T cells and inhibition of regulatory T cells, thereby improving anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current OX40 agonist antibodies are used for cancer immunotherapy, then tumor immunity can be activated, but potential risks and limitations in clinical trials remain
Solution Approach 1:
The patent segments the antibody structure by focusing on specific heavy chain variable region sequences with particular CDR configurations (SEQ ID NOs: 1-12) that bind to distinct epitopes on OX40, creating differentiated antibody variants with improved safety profiles while maintaining tumor immunity activation
Solution Approach 2:
The patent changes the binding parameters by designing antibodies with specific amino acid sequences in the heavy chain variable region (SEQ ID NOs: 1-12) that alter affinity and specificity for OX40, enabling differentiated therapeutic profiles with reduced clinical risks
2Reliability
If antibodies with high affinity binding to OX40 are designed, then activation of effector T cells and inhibition of regulatory T cells is enhanced, but complexity of antibody design increases
Solution Approach 1:
The patent applies local quality by designing specific CDR regions (SEQ ID NOs: 1-12) within the heavy chain variable region to target particular epitopes on OX40, achieving enhanced effector T cell activation and Treg inhibition through localized sequence optimization rather than overall structural complexity
Solution Approach 2:
The patent achieves multi-functionality by designing antibodies that simultaneously activate effector T cells and inhibit regulatory T cells through the same OX40 binding mechanism, using universal heavy chain variable region sequences (SEQ ID NOs: 1-12) that confer dual therapeutic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies and nanobodies demonstrate specific binding to OX40 with tight affinity, activating the NF-κB signaling pathway and competing with OX40L for binding, which can lead to improved anti-tumor immune effects and potentially better clinical outcomes in cancers such as colorectal and glioblastoma.
Implementation Method 1
The antibodies and nanobodies demonstrate specific binding to OX40 with tight affinity, activating the NF-κB signaling pathway and competing with OX40L for binding
Data Source
AI summary
The present disclosure provides antibodies that bind to OX40 and antigen binding fragments thereof, and use of the antibodies and the antigen binding fragments in the treatment of diseases for example cancers. The antibodies or the antigen binding fragments include a heavy chain variable region including one or more CDRs having an amino acid sequence selected from amino acid sequences as set forth in SEQ ID NOs: 1-12.